Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07643467 · ClinicalTrials.gov registry record · Phase 4
Fluorescent Probe for Assessment of Renal Elimination
A Phase 4 study, sponsored by Aaron Cook.
- Not yet
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
NCT07643467 is a Phase 4 study that has not yet begun recruiting, run by Aaron Cook. The registered enrollment target is 200 participants.
The verdict
NCT07643467, a Phase 4 study, has not yet begun recruiting, sponsored by Aaron Cook.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
Study Summary
Accurate measures of kidney function is important for precision dosing of many medications. The current methods of determining kidney function largely hinge on the use of equations that use common laboratory values such as serum creatinine \& static variables like age \& weight. These are helpful for trending over time, but often are inaccurate during times of medical illness. Other more accurate methods of measuring kidney function include urine collection, although this is not commonly used because of various reasons that make the collection inconvenient or unreliable. The new transdermal glomerular filtration (tGFR) device permits accurate, real-time evaluation of kidney function. This novel method has not been rigorously compared with urine collection \& other methods of determining kidney function in hospitalized patients. The goal of the study is to compare tGFR with other accepted methods of determining kidney function.
Interventions
- DRUG Iohexol
- DRUG Relmapirazin
- DEVICE Medibeacon tGFR monitor
- DIAGNOSTIC_TEST Urine creatinine clearance collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07643467
The ClinicalTrials.gov registry entry for NCT07643467 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aaron Cook, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Iohexol is the first listed.
NCT07643467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07643467 about?
NCT07643467 is a clinical study titled "Fluorescent Probe for Assessment of Renal Elimination". Accurate measures of kidney function is important for precision dosing of many medications. The current methods of determining kidney function largely hinge on the use of equations that use common laboratory values such as serum creatinine \& static variables like age \& weight. These are helpful fo...
What is the current status of trial NCT07643467?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2026-07. Estimated completion is 2028-06-30.
What interventions are being tested in trial NCT07643467?
The interventions under investigation include: Iohexol (DRUG), Relmapirazin (DRUG), Medibeacon tGFR monitor (DEVICE), Urine creatinine clearance collection (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07643467?
This trial is sponsored by Aaron Cook, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.